global public health by Paul Yager et al.
Microfluidic systems can be designed to obtain and process measure-
ments from small volumes of complex fluids with efficiency and speed, 
and without the need for an expert operator; this unique set of capabili-
ties is precisely what is needed to create portable point-of-care (POC)   
medical diagnostic systems
1,2. Fortunately for the microfluidics field, the 
military has always had a need to practise medicine in challenging and 
resource-limited environments, and so has long been trying to acquire 
robust medical technologies that add an absolute minimum to the bur-
den of those people and machines transporting them. It was for this 
reason that microfluidics research in the United States was given a great 
boost in the 1990s by funding from the US Defense Advanced Research 
Projects Agency (DARPA). The technologies developed with DARPA’s 
support (for examples, see www.darpa.mil/MTO/mFlumes) have the 
characteristics needed for delivering appropriate medical diagnos-
tics to the world’s poorest people. Today, the potential of microfluidic 
technologies to enhance the decentralization of medical testing is 
becoming accepted as one element in the next stage in the evolution of 
healthcare. Thanks to an upsurge in interest in (and funding of) health-
care in the developing world, combined with a slow pace of change 
in the developed world, this new microfluidic diagnostic technology 
(MDT) may be adopted first for civilian healthcare in the developing 
world. Some initial steps towards designing appropriate microfluidic 
diagnostic systems are described here. 
Overview of global health issues
In recent decades, substantial progress has been made in public 
health, but this progress has not been equal in developed and devel-
oping countries. The benefits and services that we in the West take 
for granted are often inadequate or lacking in many developing coun-
tries
3,4. For example, of the world’s population of 6.1 billion people, 
3 billion lack basic sanitation, 2 billion do not have access to elec-
tricity and more than 1 billion lack basic healthcare services and 
clean drinking water
5,6. For every public health triumph such as the 
eradication of smallpox, other infectious diseases such as tubercu-
losis and malaria have re-emerged, accompanied by new diseases 
such as HIV/AIDS (Fig. 1). More than half the deaths in the poorest 
countries are the result of infectious diseases (compared with less 
than 5% in the richest)
7,8. Global health, poverty and development 
are interdependent. Endemic poverty is a significant impediment to 
improving health
9. One billion, or half of the world’s children, live 
Microfluidic diagnostic technologies for 
global public health
Paul Yager
1, Thayne Edwards
1, Elain Fu
1, Kristen Helton
1, Kjell Nelson
1, Milton R. Tam
2 & Bernhard H. Weigl
3
The developing world does not have access to many of the best medical diagnostic technologies; they 
were designed for air-conditioned laboratories, refrigerated storage of chemicals, a constant supply of 
calibrators and reagents, stable electrical power, highly trained personnel and rapid transportation of 
samples. Microfluidic systems allow miniaturization and integration of complex functions, which could move 
sophisticated diagnostic tools out of the developed-world laboratory. These systems must be inexpensive, 
but also accurate, reliable, rugged and well suited to the medical and social contexts of the developing world.
1Department of Bioengineering, Box 355061, University of Washington, Seattle, Washington 98195, USA.
27501 21st Avenue NE, Seattle, Washington 98115, USA. 
3PATH (Program for Appropriate 
Technology in Health), 1455 NW Leary Way, Seattle, Washington 98107, USA
in poverty. Health indicators for mothers, newborns and children in 
many of the poorest countries have remained the same or have even 
declined in recent years
10. 
Until recently, diagnostic tests were not routinely developed primarily 
for developing-country markets, although two exceptions are the 
Program for Appropriate Technology in Health (PATH) HealthTech 
initiative, discussed below, and Helen Lee’s diagnostics development 
programme at the University of Cambridge, UK. Led by the Bill & 
Melinda Gates Foundation, initial funding has been provided to search 
for innovative technologies and solutions, including development of 
new in vitro diagnostic tests and test platforms, for the world’s neglected 
diseases
11. The US National Institute of Allergy and Infectious Disease is 
also funding an in vitro diagnostics development programme for biode-
fence to address these issues
12. Three additional initiatives that focus on 
the development of diagnostic tools are funded by the UK Department 
for International Development
13, the Foundation for Innovative New 
Diagnostics, Geneva, Switzerland (www.finddiagnostics.org) and the 
Doris Duke Charitable Foundation (www.ddcf.org). 
Figure 1 | Disability-adjusted life years (DALYs) for infectious and parasitic 
diseases.  To properly reflect the full impact of a disease, disease burdens 
can be measured in DALYs by adding the years of life lost by a person’s 
premature death to the time lived with a disability. Infectious and parasitic 
diseases accounted for almost 30% of all DALYs and 15 million deaths each 
year worldwide. Shown are the infectious and parasitic diseases responsible 
for the DALYs in 2005 (figures from the US Centers for Disease Control and 
Prevention). 
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to be rapid, simple to use (that is, requiring little in the way of facilities, 
equipment or training), low-cost or cost-effective, easily interpretable, 
and stable when transported and stored under extreme conditions. For 
some infectious agents, tests are needed to better distinguish past from 
current infections. For others, improved POC methods are needed to 
return same-day test results so that patients can receive appropriate 
therapy while they are still at the clinic. Multiplexed tests are especially 
needed to accurately identify the aetiologic agent causing a disease that 
could have multiple causative agents, such as acute lower respiratory 
infections, diarrhoeal diseases, acute onset fevers and sexually transmit-
ted infections. Global health programmes are significantly hindered 
because such tests are currently unavailable. There is also need for 
individual tests for emerging and re-emerging diseases such as tuber-
culosis, severe acute respiratory syndrome (SARS) and influenza, as 
well as vaccine-treatable diseases such as measles, tetanus and polio. 
For HIV/AIDS, better and more appropriate tests are needed for early 
diagnosis, case management and treatment monitoring of patients. For 
tropical diseases, the more urgent needs include those for leishmaniasis, 
trypanosomiasis and malaria case management and test-of-cure.
Diagnostic tools used in developed-world centralized labs 
Microfluidic instrumentation can be and has been applied to several 
of the four most common centralized laboratory techniques — blood 
chemistries, immunoassays, nucleic-acid amplification tests and flow 
cytometry. 
Basic blood chemistry panels consisting of 12 to 20 tests are routinely 
run on automated analysers to monitor a wide range of physiological 
functions. Analytes include blood enzymes, gases, electrolytes, lipids, 
thyroid indicators and drugs. Immunoassays in a wide range of formats 
allow quantification and monitoring of small molecules, large proteins 
and even whole pathogens. Simple and rapid immunoassays such as 
lateral flow strip tests (see below) can also be used in clinics or are avail-
able over the counter for home use. Blood, plasma, serum, urine, salivary 
fluids and other exudates are all used as samples. Nucleic-acid amplifica-
tion tests, such as the polymerase chain reaction (PCR) and nucleic-acid 
sequence-based amplification, have been developed that can detect very 
small copy numbers of specific nucleic-acid sequences. Test kits are now 
commercially available for tuberculosis, HIV and sexually transmitted 
infections (STIs). Test sensitivity and specificity often exceed that of 
immunoassays and culture methods
14. ‘Real-time’ PCR testing is now 
capable of producing a quantitative result in 20–30 minutes
15, 16. Flow 
cytometry is the method of choice for counting cells with specific physi-
cal and/or chemical characteristics. Great strides towards miniaturiza-
tion, including work now published for a decade about microfluidic 
devices, have been made
17,18. 
These technologies are well suited to small and large laboratories in the 
developing world, assuming that the technicians employed to use them 
have a relatively high level of training. However, in places with lower lev-
els of training, or away from venues with continuous power and, hence, 
refrigeration, these technologies have been less applicable. Microfluidics 
may be able to close the gap between what can be done now and what 
needs to be done at the remotest ends of the healthcare system, where the 
vast majority of the developing world’s population resides. 
End-users of microfluidic diagnostics in the developing world
The centralized laboratory model found in the developed world is not 
widely applicable in developing nations. Where such centralized labo-
ratories exist at all, most are found in large cities, catering primarily for 
the affluent few. Healthcare facilities in rural areas commonly have only 
basic equipment, healthcare workers may have little training, and the 
resources to maintain complex equipment and handle fragile reagents 
are often limited. Three tiers of healthcare providers can be identified 
in developing countries: capital- or major-city-level hospitals; district-
level healthcare providers (Fig. 2); and village-level healthcare work-
ers. However, the actual level of care provided at each site can vary 
considerably. 
Typical conditions in a laboratory in a mid-level healthcare centre in a 
developing country are rather different from those in a developed-world 
mid-level clinical laboratory. Running water and electricity may or may 
not be available, but power is at best intermittent with wide fluctua-
tions in voltage. The ambient temperature may range from 10 to more 
than 40 
oC. Dust, wind and contaminating pathogens are very common. 
Potentially high-risk human samples, containing biosafety level (BSL)-2 
and -3 pathogens are routinely handled with few precautions other than, 
perhaps, gloves. Maintaining and calibrating even moderately complex 
instruments still presents a challenge. However, it may be possible to 
perform microscopy, most lateral flow assays, some blood chemistry 
and cytology, and some enzyme-linked immunosorbent assays (ELISAs) 
in these labs.
At the periphery of the medical care system — in townships and 
villages — power, running water and refrigeration are often intermit-
tent or absent. Whatever assays are to be performed must therefore be 
completely self-contained. Devices must be battery-operated, require no 
maintenance or calibration, be dust-proof, be easily secured at night, and 
operate at a wide range of ambient temperatures. Village-level health-
care workers are, for most of the population, the only or main source of 
healthcare; such health workers can sometimes perform basic strip or 
dipstick tests for pregnancy, HIV and, in some cases, malaria and STIs. 
Test results must be presented in a very simple, yes/no way to avoid 
misinterpretation. To bring a more sophisticated set of diagnostic capa-
bilities to such environments is a challenge of both technical function 
and development of an appropriate user interface. 
Potential benefits of microfluidic diagnostic systems 
During the past decade in the developed world, near-patient testing 
using POC devices has become established for doctors’ offices, stat labs 
and, in rare cases, in the home (for example, glucose monitors). Interest 
in moving to a more patient-centric POC/home-testing approach is on 
the rise in the developed world
19. Microfluidic lab-on-a-chip technol-
ogy may now suit both developing- and developed-world applications. 
Many of us believe we will soon have microfluidics-based POC and 
home-care devices that can perform assays at sensitivity, specificity and 
reproducibility levels similar to those of central laboratory analysers, 
but yet require little user input other than the insertion of the sample. 
Such devices could, in the hands of developing-country lay people, 
perform routine testing, or detect the presence of an infectious agent 
with epidemic potential such as influenza, an opportunistic infection, 
or a chronic health condition, and provide guidance to the end-user. 
That same diagnostic platform, loaded with different reagents, could, 
in the hands of a village healthcare worker, detect the aetiological agent 
causing acute fever or diarrhoea, and provide information on what, if 
any, therapy should be given to the patient. However, the cost of the 
hypothetical microfluidics-based diagnostic tool must be extremely 
low if it is to be applicable to the developing world. 
Potential benefits of distributing diagnostic devices and systems 
designed specifically for developing countries include: access to diag-
nostic tools not previously available, and thus faster/more accurate 
diagnoses; better epidemiological data that can be used for disease mod-
elling, vaccine introduction and to define the economics of a healthcare 
system; better utilization of minimally trained healthcare workers; and 
better use of existing therapeutics.
Figure 2 | Two typical laboratories in mid-level healthcare centres in the 
developing world.  Note the wide range of conditions in which healthcare 
workers operate. (Images courtesy of B. H. W. and colleagues, PATH, USA.)
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There are three approaches to diagnostic technologies that have been 
used in the developed world: permanent integrated instruments, pure 
disposables and permanent instruments that use disposable compo-
nents. All can be and have been adapted for use in the developing world, 
but they are not equally applicable to specific problems. 
Permanent integrated instruments
The permanent integrated instrument is the mainstay of the centralized 
laboratory in the developed world. These systems are well suited to 
high-throughput work, but generally require an infrastructure that can-
not usually be provided in developing countries. Even if such an instru-
ment could be scaled down (and made affordable enough) to work in 
resource-limited settings, the requirement that the instrument purge 
itself of one sample before analysing another (preventing carryover) and 
that it be frequently calibrated with standards, and rinsed with cleaning 
solutions, is not in keeping with the setting. This approach is, therefore, 
unlikely to be successful, particularly in the most impoverished settings, 
even with microfluidic components. 
Disposables
Lateral flow or immunochromatographic strip (ICS) tests have been, 
for the past decade, one of the very few diagnostic technologies to be 
successfully used in the developing world, and are, therefore, the tech-
nology that microfluidics must complement or supplant. They provide 
POC diagnosis in areas without access to well-equipped and well-staffed 
clinical laboratories. They rely on relatively inexpensive, off-the-shelf 
components and reagents, are amenable to large-scale production meth-
ods, and are relatively affordable. They can be formatted for detection 
of either antigens or antibodies, and are usable with a wide range of 
specimens. Most are stable at ambient temperatures for more than a 
year when appropriately packaged and can be shipped without refrig-
eration. The analytical performance of some POC lateral flow tests are 
comparable to reference-level laboratory methods
3.
ICS tests developed by PATH, with support from the United States 
Agency for International Development (USAID) can diagnose diphthe-
ria toxin
20,21–27 and a number of STIs
28, including gonorrhoea (Neisseria 
gonorrhoeae) (Fig. 3), syphilis (Treponema pallidum)
29, chancroid 
(Haemophilus ducreyi)
20 and chlamydia (Chlamydia trachomatis)
28,30–32. 
The early diagnosis offered by some strip tests, together with the ability 
to provide appropriate therapy to patients before they leave the clinic, 
has proved useful to control the spread of the diseases
33. In addition to 
STI assays, PATH has developed, co-developed, or introduced assays 
for retinol-binding protein (as a marker for vitamin A deficiency)
34, 
P. falciparum malaria
30–32, HIV
25,29, hepatitis B
24, the hormone human 
chorionic gonadotropin (indicating pregnancy), faecal leukocytes and 
proteinuria
20–23,26,28.
Health workers can quickly learn to perform such ICS-based tests and 
require infrequent retraining. However, some such tests are still not suf-
ficiently sensitive or specific for accurate POC use. For example, PATH’s 
malaria test, which can only detect P. falciparum
31, must be used with 
care in hyperendemic areas, where many individuals may have low titres 
of circulating P. falciparum antigens, leading to an excess of false positive 
results. Parasite antigens may persist in circulation even after successful 
therapy, and could produce confusing results with P. falciparum tests 
when assessing test-of-cure or drug resistance. The visual readout of the 
strip is usually limited to a yes/no answer; this is not adequate when the 
level of an analyte is important. Sophisticated sample preconditioning 
(which is needed for many assays) is also impossible in many areas. 
Disposables with a reader
The compromise that allows high performance with low per-test cost, 
but with added complexity, is to use a ‘reader’ with single-use dispos-
ables. The sample and waste are retained within the disposable, so the 
reader does not need to be cleaned between samples. Calibrants can 
also be stored on the disposable. At the University of Washington, we 
are developing a system for monitoring analytes in saliva using surface 
plasmon resonance (SPR) imaging
35–37. The aim of the salivary diag-
nostics system is to measure small-molecule analytes such as hormones 
and drugs in whole saliva. The use of saliva is a suitably challenging 
problem, and one that would translate well to use in the developing 
world. The ‘disposables with a reader’ model seems to us to be the most 
promising approach as a powerful and versatile format that can meet the 
demands of the developing-world setting. Below, we consider in more 
detail the challenges to overcome for this diagnostic platform.
The first challenge is to process complex biological samples without 
the sophisticated sample preconditioning capabilities (human or 
mechanical) available in centralized labs. Centrifugation, which might 
be available in a mid-level laboratory to provide a purified plasma 
sample from blood, will not be available in a remote setting. There are 
uniquely microfluidic solutions to these issues, such as the H-filter
38–41, 
which was conceived as an alternative to a conventional porous barrier 
filter (Fig. 4). The H-filter can be used to limit the size of analytes that 
proceed downstream to a detection module from non-blood samples 
such as saliva, at the cost of requiring controlled flow to three of the 
four ports of the device. However, for single-use disposables, a conven-
tional filter may be adequate for removing cellular components from 
blood prior to analysis. In the case of the salivary diagnostics system, 
it was found that saliva contained molecules that rapidly bound to the 
SPR detection surface, adding unacceptable background signal, so 
Negative test result
a
Positive test result Syphilis ICS test bc
Absorbent pad
Sample pad
Colloidal gold-antigen
conjugate
Plastic-backed
nitrocellulose membrane
Test line
Control line
Figure 3 | Rapid immunochromatographic strip (ICS) tests for sexually transmitted infections.  a, A schematic of the ICS assay format. b, c, Tests for 
gonorrhoea (b) and syphilis (c) are shown.
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dielectrophoresis and isoelectric focusing are three other techniques 
that can also be used, and have been used extensively in lab-on-a-chip 
systems
42–51. The electrokinetic methods can add cost if they require 
electrodes to be present in the disposable itself.
One of the great strengths of microfluidics is the ability to integrate the 
steps of a complex chemical process into a monolithic disposable — an 
assay performed in such a way can be more precise, more accurate and 
more reproducible than the same assay performed by hand. An example 
of an integrated assay is shown in Fig. 5, in which many of the steps of 
analysis of a whole saliva sample (subsequent to mechanical filtration) 
are integrated into a disposable diagnostic card. In this card, the sample 
is isolated and the waste is retained, and sample contact with the elec-
trical and optical components of the permanent instrument is avoided. 
Note that not all of the challenges of integration have been accomplished 
in the current design; for example, external pumps and off-chip sample 
preprocessing are required. However, two other projects that are under-
way (and described briefly below) will produce disposables that fully 
integrate all fluidic functions.
The selection of a material for use in a disposable must balance the 
inherent cost of the material with processing costs. Many polymers are 
inherently inexpensive, but the cost of processing to make them com-
patible with device function can add substantially to the total cost of 
the disposable. For example, microfluidic materials must be selected 
to minimize surface adsorption of analytes and to allow those analytes 
to move to the detection zones in the disposables. A material can be 
inherently nonfouling, but more often must undergo a coating process 
to be made so. An inherently low-cost material may be more difficult to 
chemically modify and would increase the complexity of manufacturing 
and the final cost of the disposable. 
Often, selection of a material will be dictated by application require-
ments. For example, in applications that require fluorescence-based 
detection of small-molecule analytes, low fluorescence (and low light 
scattering) is a selection criterion for acceptable device materials in 
the optical path
52. One material, poly(dimethylsiloxane) (PDMS), is 
excellent for fabrication of low-fluorescence devices, but is perme-
able to many small and hydrophobic molecules, and is not readily or 
economically formed in high-throughput production. Thermoplastics 
such as polystyrene are ideal for high-level production because they can 
be injection molded, although not all have optimal optical properties. 
Whereas lamination of laser-cut polymer sheets is extremely cost-effec-
tive for rapid prototyping
53, it is not nearly as economical as injection 
moulding for production of large numbers of devices. Although mixing 
different materials is complex, it may often be necessary. Note that in 
the laminated disposable example (Fig. 5a), PDMS was used to form a 
herringbone mixer
54 with small features, largely because the CO2 laser 
(used to form the Mylar layers) had too low a spot resolution. Also, 
the gold SPR imaging surface was formed on a glass microscope slide 
because it was less expensive to manufacture them this way than to 
purchase small lots of gold films of a precise thickness on polymers. The 
fragility of glass makes it unsuitable for use in a commercializable dis-
posable for POC diagnostics. Real devices will always have to combine 
multiple materials. 
Because one of the fundamental requirements for a microfluidic diag-
nostic disposable is extremely low cost (ideally pennies), the disposables 
must be designed to have few parts and be inexpensive to manufacture, 
ideally using injection moulding whenever possible. These criteria rule 
Figure 4 | Schematic of an H-filter.  This is a microfluidic device that allows 
convenient extraction of small molecules from complex fluids into simpler 
buffer streams. Initial attempts to use the H-filter alone to extract small-
molecule analytes from whole saliva failed because of the high viscosity 
and non-newtonian behaviour of the solution. It was therefore necessary 
that the concentration of mucins be reduced before the saliva entered the 
H-filter (manuscript in preparation, K.H., B. Finlayson and P.Y.). Note also 
that in the disposable card in Fig. 5, the H-filter channels were configured 
to allow greater contact between the two flowing streams. 
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Figure 5 | Example of an integrated disposable diagnostic card.  a, Image of 
a card. The red O-rings are for interfacing with off-card components (for 
example, valves and pumps) that will eventually be incorporated onto the 
card itself. b, Schematic of the card. The card accepts filtered saliva (see 
Table 2) from the syringe and contains an H-filter for further sample 
conditioning, a herringbone mixer for mixing antibodies with the sample, 
and channels with gold-coated surfaces for detection of analyte in the sample 
using an SPR imaging-based immunoassay (manuscript in preparation, 
T.E. et al.). Numbers in ovals are flow rates in nl s
–1. Numbers at the H-filter’s 
four ports are the percentages of flow entering (right) and exiting (left) the 
device. MB, mixing buffer; HB, H-filter buffer; HV, H-filter vacuum; R1 and 
R2 are reference solutions, typically a positive and negative control. 
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of its small size. Ideally, these controls will be present on the disposable 
itself, so that every measurement will be made at the same time as the 
calibration runs. This will put a heavy burden on the preservation of the 
reagents in the disposable. In the salivary diagnostics project, we have 
developed microfluidic methods for running calibrations alongside the 
critical measurements by patterning reagents and using multiple low-
Reynolds-number fluid streams to keep detection areas discrete. Such 
methods allow measurement of binding rates of analytes to surfaces in 
samples such as saliva in just a few minutes (Fig. 6). 
The disposables themselves will be shipped and stored at ambient 
temperatures, which, in the developing world, can range from tropical to 
arctic. For vaccines, which are generally very heat-labile, the ‘cold chain’ 
has been extended to the periphery of the healthcare system. However, it 
is costly to maintain. The disposables for diagnostics must contain biologi-
cal molecules (and perhaps even entire pathogens) in addition to a range 
of organic chemicals as reagents. If they were stored in buffer at ambient 
temperature they would very rapidly be degraded. A preferred alternative, 
successfully used in lateral flow assays and recently applied to more readily 
identifiable ‘microfluidic’ systems, is to desiccate the biomolecules, replac-
ing the normal waters of hydration by sugars
55,56. This, derived in part from 
the drug-delivery field, would allow the disposable to contain only dry 
reagents, thus reducing weight, extending product stability and allowing 
transportation and storage of the MDTs at ambient temperature.
A critical aim of microfluidic diagnostics for the developing world is 
to make all steps of their use simple and as culturally independent as pos-
sible. This will be a challenge given the diversity of language, training and 
cultural backgrounds of the end-users of the technologies. For this rea-
son, extensive work with the end-users is an absolute requirement before 
designing the user interface. It is not possible to assume that the end-user 
will be the same as the users of centralized laboratory equipment. 
The future of MDTs in the developing world
Enteric infections are the second leading cause of morbidity and mortality 
worldwide, accounting for an estimated 3.1 million deaths annually, 
mostly in the developing world. Outbreaks can be controlled with rapid 
diagnosis and appropriate treatment, which can also reduce the severity 
of disease. But the developed-world standards for diagnosis of infectious 
diarrhoea — culture, enzyme immunoassay and PCR — are impracti-
cal, expensive and too slow for developing-world users. Identification 
of target pathogens, even in the best developed-world laboratory, often 
takes 2–4 days
57. 
out inherently expensive materials, complex manufacturing methods 
and expensive reagents in anything but the smallest quantities. It is also 
advisable, on cost grounds alone, to assemble and manufacture as many 
parts of the disposable as possible in the developing world. 
The disposable/reader model results in the creation of biohazardous 
medical waste of little or no value for recycling. The best method for 
disposing of such waste is incineration, but it is also possible to render 
it non-infectious by treatment with a disinfectant such as bleach, which 
could even be incorporated into the disposable in a blister pack. For 
use in remote areas, thought should therefore be given to producing an 
efficient, safe and verifiable method for incinerating disposables using 
local facilities. 
The microfluidic diagnostic end-users will need a supply of dispos-
ables. The disposables will need to be robust, as they will be transported 
at ambient temperatures. Beacause the disposables will be hand-carried, 
their weight must be minimal. Large, centralized instruments frequently 
require large volumes of pre-made buffers and reagent solutions to oper-
ate. Fluid reservoirs contribute substantially to the bulk of the instru-
mentation (and the revenue stream of the manufacturers). Because water 
is heavy, there is a clear incentive to ship the disposables dry, and use 
local sources of purified water. 
Although lateral flow strips and related technologies do not require 
power to operate, instruments currently used in centralized laboratories 
are designed with no consideration of their electrical requirements. For 
a field-portable instrument, the assumption is that electrical power will 
either be nonexistent, or limited to automobile generators, photocells, 
hand-generators, or other low-capacity power sources. As a consequence, 
MDT systems must be designed from the ground up to use a minimum 
amount of power, and if the disposables store power, it must be in clever 
ways — a challenging task for any but the simplest (and least quantita-
tive) assays. Such high-precision assays — for example, those requiring 
thermal cycling (such as PCR and related nucleic-acid amplification 
technologies) — require a lot of power in their current embodiments, so 
there is room for creative engineering to develop inherently low-power 
methods of changing sample temperature. What power sources may 
be used (other than external ones) must be compact and lightweight. 
Great advances made during the last few years in small, recharge-
able batteries will help, but there is clearly scope for improvement 
in this area too.
A successful microfluidic diagnostic technology will be self-calibrat-
ing, carrying all necessary reagents to run positive and negative controls 
along with it. This is particularly necessary for a POC instrument, which 
Figure 6 | Quantification of a competitive immunoassay for phenytoin using surface plasmon resonance (SPR).  a, SPR difference image used to quantify a 
competitive immunoassay for phenytoin (manuscript in preparation, K.N. et al.). The detection zone is a gold surface precoated with bovine serum albumin 
(BSA) covalently modified by phenytoin. The three streams (750 nl s
–1) contained 150 nM anti-phenytoin antibody mixed with 0 nM, 50 nM or 100 nM 
soluble phenytoin (bottom to top, respectively). The contrast in the image has been adjusted to highlight the differences between the nonfouling polyethylene 
glycol (PEG) upstream and the three sample regions. b, c, Competition assay detection of low-end therapeutic levels of phenytoin in a model system (b) and 
in preconditioned saliva (c). b, SPR reflectivity over time of anti-phenytion antibody in phosphate buffer binding to a BSA–phenytoin-treated surface. The 
plot shows that the rate of antibody binding negatively correlates with the amount of competitor (phenytoin) added to the solution. c, SPR reflectivity of 
variously treated preconditioned saliva samples over time. In this case, whole human saliva was preconditioned using a mechanical filter and the H-filter off-
card. Plots b and c show that the PEG region effectively resisted fouling to either antibody or components present in preconditioned saliva.
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Nature  PublishingGroup   ©2006Work has begun on a ‘disposable with reader’ lab-on-a-chip plat-
form for identification of the pathogens — Shigella dysenteriae type 1, 
Shiga toxin-producing Eschcherichia coli (O157:H7), Campylobacter 
jejuni and Salmonella — that commonly cause acute enteric disease 
with similar symptoms. The diagnostic assay comprises the disposable 
single-use microfluidic card, containing dry, heat-stable agents and a 
permanent hand-held instrument to operate the microfluidic circuits 
and control the card’s temperature. The user will insert a swab contain-
ing a stool sample into the card and place the card in the instrument. 
The card will include four microfluidic subcircuits: organism capture 
and lysis from raw stool; nucleic-acid capture; multiplexed nucleic-
acid amplification; and visual detection of amplified PCR products. 
A combination of capillary action and positive displacement pumping 
will draw the sample via microfluidic channels through the integrated 
subcircuits on the disposable. A positive control (E. coli, present in any 
stool sample) will be included to demonstrate proper sample process-
ing, and to validate negative results. The complete sequence will take 
less than 30 min. Early tests show that sensitivity and specificity are 
comparable to the results achieved with conventional microbiological 
and PCR assays
58, and the cost is expected to be between US$1 and 
$5 per disposable. 
The Gates Foundation’s Grand Challenges in Global Health initiative 
is supporting the development of prototypes of a disposable/ hand-held 
reader system, which will include the reagents for both immunoassays 
and nucleic-acid amplification tests, requiring only a couple of drops 
of blood from the patient for a readout. Initial focus is on the develop-
ment of tests for simultaneous detection of infectious agents that cause 
diseases associated with rapid onset fever, including malaria, typhoid, 
dengue, rickettsial diseases, measles and influenza. Because of the ability 
to perform both immunoassays and nucleic-acid amplified tests, this 
platform could ultimately process a wide range of disease panels.
The current funding climate for the development of diagnostics for 
developing countries is good, thanks to vastly increased interest in global 
health, stoked by initiatives from private foundations and institutions. 
Additionally, significant funding of pathogen diagnostics development 
is available through United States government sources
12, although 
primarily driven by biodefence concerns, as many of the organisms 
that could be weaponized also cause disease in developing countries 
(www3.niaid.nih.gov/biodefense/bandc_priority.htp). Donors and 
international agencies support the need for new and improved diagnostic 
tools for priority diseases; advocacy and technology development groups 
have been formed, such as the STD Diagnostics Initiative
59 and the 
Tuberculosis Diagnostics Initiative
60, with secretariats within the World 
Health Organisation/Special Programme for Research and Training 
in Tropical Diseases (WHO/TDR). These are good beginnings, but 
because the marketplace for medical diagnostics is fragmented in the 
developing world, no single strategy will ensure distribution of new 
technologies as they are developed. 
Although we feel strongly that the development of appropriate 
diagnostic technologies is an important factor in the goal of improv-
ing global public heath, significant improvements in the health of the 
developing world will only be achieved if there is tight coordination 
between the diagnostics developers and the communities involved in 
local education, drug discovery and drug distribution. Long-term, suc-
cessful use of MDTs in the developing world will require the sustained 
efforts of these communities. 
There are a number of key factors that will affect the introduction, 
acceptability and sustainability of these technologies (summarized in 
Table 1). One of the greater challenges in deploying microfluidic diag-
nostic systems in the developing world will be bringing the cost down 
close to the cost of the most inexpensive of current tests, namely the 
lateral flow immunoassays (it should be borne in mind that the actual 
cost of using these immunoassays does include that of misdiagnosing 
patients). Thanks to increased interest on the part of the global health 
community, we expect to see the introduction of microfluidic diagnostic 
devices specifically designed for the developing world within the next 
5 years.   ■
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